CloudScreen is a next generation “one-stop-shop” platform for drug repositioning

CloudScreen is a next generation “one-stop-shop” platform for drug repositioning and repurposing. 1D and 3D data are integrated to reveal the drugable proteome and variome (proteoforms). Efficacy and toxicity predictions are the net outcome of AI and human synergies.

This research is supported by the European Regional Development Fund of the European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCHCREATEINNOVATE (project code: T2EDK-03153)


National Hellenic Research Foundation (NHRF), one of the largest research centres in Greece, was founded in 1958. It is a non-profit Research Foundation supervised by the General Secretariat for Research and Technology (GSRT) of the Ministry of Development and Investments in Greece.
The Institute of Chemical Biology (ICB) at NHRF act as a focal point of Excellence, through an interdisciplinary approach in the area of Chemical Biology with the aim of providing solutions for state-of-the-art issues in the areas of health, drug research, and biotechnology. In Greece, no other Institute currently employs an analogous integrated multidisciplinary approach to disease prevention and treatment relying on the exploitation of the synergy between Chemistry and Biology, the expertise of its research staff and its state-of-the-art infrastructure. In this capacity, IBMCB promotes national research priorities on ‘Biomedicine and Health’, ‘Agrobiotechnology and Food’, and ‘Energy and Environment’ as tools for national economic growth (see report McKinsey & Co. “Greece 10 years ahead”).
The Biomarker Discovery & Translational Research Laboratory at NHRF aims to map inter-individual variability and unmask xenobiotics for ADME-Tox profiling, informed drug repurposing and companion biomarkers. Multi-omics, 3D cell models, and microfluidics serve as a toolbox.

Cloudpharm is a bio-pharmaceutical R&D Company founded and established in Greece in 2016. Its core business focuses on the discovery of bioactive compounds with pharmacological interest, emphasizing on natural products. Moreover, Cloudpharm provides services for drug identification protocols, as well as in silico services for drug design and discovery and drug repositioning. Furthermore, Cloudpharm has developed large virtual chemoinformatics libraries of synthetic and natural compounds from around the globe that could potentially be used as lead molecules towards new active pharmaceutical ingredients.

Our scientific expertise in the field of drug discovery, the wide network of collaborators and the efficient cloud and IT resources aim to deliver integrated solutions to the pharmaceutical industries. More specifically, using highly specialized software dedicated to various computational techniques, Cloupharm focuses in:

1. Machine learning and AI applications in drug repurposing

2. Virtual Screening of natural products to identify their potential pharmaceutical applications

3. Target assessment of proteins with pharmaceutical interest

Cloudpharm creates value. It is a flexible and easily adoptable R&D partner to every pharmaceutical company wants to invest in innovation for the development of new products.